Soluble pharmaceutical composition for mastitis and ear involvement treatment

FIELD: medicine.

SUBSTANCE: invention refers to methods and compositions for treatment and/or prevention maintenance of infectious condition in liquid-containing organ or organ with natural external aperture. Composition includes antibacterial agent, and also, probably, other active agents, amphipathic oil which is soluble in water and insoluble in ethanol, microcrystalline wax and pharmaceutically acceptable nonaqueous carrier. The method of treatment is realised by introduction of a pharmaceutical composition in body through natural external aperture.

EFFECT: regarding composition, invention provides stability of the active agent against oxidising decomposition, low interfacial tension of composition, easy solubility in liquids, and short time of excretion; invention provides effective treatment and reduction of by-effects and toxicity.

61 cl, 12 ex

 

The text descriptions are given in facsimile form.

1. The method of treatment and/or prevention of an infectious condition in the body, containing liquid, having a natural exterior orifice, including the introduction of antibacterial agent in the body through the external opening and introduction in the de combination therapy with the specified antibacterial agent, the second agent selected from the group consisting of anesthetics, blockers of sodium channels and anti-edema agents, where specified antibacterial agent is administered in the form of pharmaceutical compositions containing the specified antibacterial agent and a filler, which contains (a) amphiphilic oil, dispersible in water and insoluble in ethanol, (b) microcrystalline wax and (C) pharmaceutically acceptable non-aqueous carrier.

2. The method according to claim 1, where the infectious condition is a disease of the udder of the animal producing the milk, and where the composition comprising the antibacterial agent is administered by infusion into the mammary gland.

3. The method according to claim 2, where the disease is mastitis.

4. The method according to claim 1, where the infectious condition is a disease of the ear of the subject or associated with such lesions complication, and where the composition comprising the antibacterial agent is administered by infusion into the ear.

5. The method according to claim 4, where the condition is chosen from the group consisting of external ear otitis, otitis of the middle ear, otorii, acute mastoiditis, earaches, ear bleeding, inflammation of the ear, ear shingles, syndrome geniculate ganglion, viral neurons, ganglionitis, herpes geniculate body, labyrinthitis, purulent labyrinthitis, fistula of perilymph, infectious myringitis, medical masingita, zlocesto the aqueous external otitis, otalgia, infection of the eardrum, tympanica, ear boils, titney hydrocephalus, Dandy, diffuse inflammation of the external ear, otomycosis, infections associated with ear surgery, and infectious complications associated with other ear diseases.

6. The method according to claim 4, where the condition is chosen from the group consisting of external ear otitis, otitis of the middle ear, otorii and infections associated with ear surgery.

7. The method according to claim 1, where the second agent is administered by different routes of administration of antibacterial agent.

8. The method according to claim 1, where the second agent is administered in the same way as an antibacterial agent.

9. The method according to claim 1, where the second agent is administered in the form of pharmaceutical compositions containing the specified second agent and the filler, which contains (a) amphiphilic oil, dispersible in water and insoluble in ethanol, (b) microcrystalline wax and (C) a pharmaceutically acceptable carrier.

10. The method according to claim 1 where the pharmaceutical composition further comprises a second agent.

11. The method according to claim 1, where the antibacterial agent is selected from the group consisting of natural and synthetic antibiotics such as penicillin, cephalosporins, macrolides, lincosamides, pleuromutilins, polypeptides, polymyxins, sulfonamides, chloramphenicol, thiamphenicol, Florent the La, antibiotics are a type of tetracycline, quinolones, fluoroquinolones, tiamulin, ciprofloxacin, colistin, demeclocycline, mafenide, metatsiklina, norfloxacin, ofloxacin, pyrimethamine, sulfadiazine silver, sulfacetamide, sulfisoxazole, tobramycin, Vanemuine, oxazolidinones, glycopeptides, aminoglycosides and iminocyclitol, amphenicol, ansamycin, carbapenem, cephamycin, vancomycin, monobactam, oxazepam, systemic antibiotics, antitumor agents, types of antibiotics, nitrofurantoin, marbofloxacin, and tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs.

12. The method according to claim 11, where the cephalosporin selected from the group consisting of ceftiofur, cephalexin, cephradine, cathinone, cefacetrile, cefpodoxime, cefovecin, Cefalonia, cefuroxime, cefazedone, cefoperazone, semecarpifolia sodium, ceema, cephalo-Smoking, Cefazolin sodium, cefoxitin, cefixime, ceftizoxime, Ceftriaxone, on-formylrifamycin, salts of derivatives of 3-acetoxymethyl-7-(aminoamide)zefalosporinovy acid, 7-(D-α-aminoα-(p-hydroxyphenyl)atsetamino)-3-methyl-3 -cefem-1-carboxylic acid, hydrochloride SYN-7-((2-amino-1-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-3-cefem-4-carboxylic acid, tsepelovo acid (pivaloyloxy)methyl-7-beta-(2-(2-amino-4-thiazolyl)acetamido)-3-(((1-(2-(dimethyl is Ino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cefem-4-carboxylate, cephalexin, 7-(D-2-naphthylacetamide)-3-methyl-3-cefem-4-carboxylic acid and tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs, and combinations thereof.

13. The method according to claim 11, where the antibacterial agent includes ceftiofur or its pharmaceutically acceptable salt or form.

14. The method according to item 13, where the antibacterial agent includes ceftiofur hydrochloride.

15. The method according to item 13, where the antibacterial agent contains crystalline free acid of ceftiofur.

16. The method according to claim 1, where the antibacterial agent includes oxazolidinone selected from the group consisting of eperezolid, linezolid, N-((5S)-3-(3-fluoro-4-(4-(2-foradil)-3-hydroxy-1-piperazinil)phenyl-2-hydroxy-5-oxazolidinyl)methyl)ndimethylacetamide, (S)-N-((3 -(5-(3-pyridyl)thiophene-2-yl)-2-hydroxy-5-oxazolidinyl)methyl)ndimethylacetamide hydrochloride and (S)-N-((3-(5-(4-pyridyl)pyrid-2-yl)-2-hydroxy-5-oxazolidinyl)methyl)ndimethylacetamide and their combinations.

17. The method according to claim 1, where the specified second agent includes an anesthetic agent.

18. The method according to claim 1, where the specified second agent includes a blocker of sodium channels.

19. The method according to claim 1, where the specified second agent contains an antitumor agent.

20. The method of treatment and/or prevention of an infectious condition in the body, containing liquid, having a natural exterior orifice, including the introduction of antibacterial agent in the body through the external is twistie and introduction to combination therapy with the specified antibacterial agent, second agent, which contains anti-inflammatory agent and anesthetic agent where specified antibacterial agent is administered in the form of pharmaceutical compositions containing the specified antibacterial agent and a filler, which contains (a) amphiphilic oil, dispersible in water and insoluble in ethanol, (b) microcrystalline wax and (C) pharmaceutically acceptable non-aqueous carrier.

21. The method according to claim 20, where the second agent includes a selective inhibitor SOH-2 and anesthetic.

22. The method according to claim 20, where the antibacterial agent is ceftiofur or its pharmaceutically acceptable salt or form; an anti-inflammatory agent selected from the group consisting of deracoxib, parecoxib, celecoxib, valdecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-differenl)-3-[4-(methylsulphonyl)phenyl]-2-cyclopenten-1-it, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-differenl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulphonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-forfinal)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzosulfimide, tert-butyl 1 benzyl-4-[(4-oxopiperidin-1-yl}sulfonyl]piperidine-4-carboxylate, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzosulfimide their salts and prodrugs; and the anesthetic is lidocaine.

23. The method according to claim 20, where the antibacterial agent is linezolid, and the second AG is NT contains a selective inhibitor SOH-2 and lidocaine.

24. The method according to claim 20, where the pharmaceutical agent further comprises a second agent.

25. Pharmaceutical composition containing a filler, which contains (a) amphiphilic oil, dispersible in water and insoluble in ethanol, (b) microcrystalline wax and (C) pharmaceutically acceptable non-aqueous carrier; where the specified filler contains stably dispersed and antibacterial agent, an antibacterial effective amount, and a second agent selected from the group consisting of anesthetics, blockers of sodium channels and antitumor agents in therapeutically effective amounts.

26. The composition according A.25 suitable for administration by infusion in the mammary gland, in the udder of the animal producing the milk, for the treatment and/or prevention of bacterial diseases of the udder.

27. The composition according to p, where bacterial disease is mastitis.

28. The composition according A.25 suitable for insertion into the ear for the treatment and/or prevention of ear infection.

29. The composition according A.25, where the antibacterial agent is selected from ceftiofur, cephalexin, cephradine, cathinone, cefacetrile, Cefotaxime, cefovecin, Cefalonia, cefuroxime, cefazedone, cefoperazone, semecarpifolia sodium, ceema, cephalo-Smoking, Cefazolin sodium, cefoxitin, cefixime, ceftizoxime, Ceftriaxone, formulaf the Mandola, salts of derivatives of 3-acetoxymethyl-7-(aminoamide)zefalosporinovy acid, 7-(D-α-aminoα-(p-hydroxyphenyl)atsetamino)-3-methyl-3-cefem-1-carboxylic acid, hydrochloride SYN-7-((2-amino-1-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-3-cefem-4-carboxylic acid, acid cafema (pivaloyloxy)methyl-7-beta-(2-(2-amino-4-thiazolyl)acetamido)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cefem-4-carboxylate, cephalexin, 7-(D-2-naphthylacetamide)-3-methyl-3-cefem-4-carboxylic acid, tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs, and combinations thereof.

30. The composition according A.25, where the antibacterial agent includes ceftiofur or its pharmaceutically acceptable salt or form.

31. The composition according A.25, where the antibacterial agent includes ceftiofur hydrochloride.

32. The composition according A.25, where the antibacterial agent includes crystalline free acid of ceftiofur.

33. The composition according to item 30, where the antibacterial agent is present in a concentration of from 1 to 1000 mg/ml

34. The composition according to item 30, where the antibacterial agent is present in a concentration of from 5 to 750 mg/ml

35. The composition according to item 30, where the antibacterial agent is present in a concentration of from 10 to 100 mg/ml

36. The composition according A.25, where the antibacterial agent contains oxazolidinone selected from the group consisting of eperezolid,linezolid, N-((5S)-3-(3-fluoro-4-(4-(2-foradil)-3-hydroxy-1-piperazinil)phenyl-2-hydroxy-5-oxazolidinyl)methyl)ndimethylacetamide, (S)-N-((3-(5-(3-pyridyl)thiophene-2-yl)-2-hydroxy-5-oxazolidinyl)methyl)ndimethylacetamide hydrochloride and (S)-N-((3-(5-(4-pyridyl)pyrid-2-yl)-2-hydroxy-5-oxazolidinyl)methyl)ndimethylacetamide.

37. Composition according to any one of p-36, where the amphiphilic oil is poliglecaprone-glycerides obtained by the reaction of an alcohol of hydrolysis of natural triglycerides with propylene glycols.

38. The composition according to clause 37, where poliglecaprone the glycerides contains the main fatty acid component of oleic or linoleic acid.

39. The composition according to clause 37, where poliglecaprone the glycerides contains the main fatty acid component of oleic acid.

40. The composition according to clause 37, where poliglecaprone the glycerides is pericola 5-oleate.

41. The composition according to clause 37, where the amphiphilic oil is from 0.01% to 99 wt./vol.% song.

42. The composition according to clause 37, where the amphiphilic oil is from 1% to 80 wt./vol.% song.

43. The composition according to clause 37, where the amphiphilic oil is from 3% to 25 wt./vol.% song.

44. Composition according to any one of p-36, where the microcrystalline wax is from 0.001 to 50 wt./vol.% song.

45. Composition according to any one of p-36, where the microcrystalline wax is from 0.1 to 40 wt./vol.% song.

46. Composition according to any one of p-36, where microcrystalline wax is from 1 to 15 wt./vol.% song.

47. Composition according to any one of p-36, where non-aqueous carrier selected from the group consisting of vegetable oils, mineral oils, fatty acids with medium chain length and long chain fatty acids and their esters, propylene glycol diesters of fatty acids with medium chain length and long chain fatty acids, mono-, di - and triglyceridemia esters of fatty acids, polyethylene glycols, and combinations thereof.

48. The composition according to p, where non-aqueous carrier is a vegetable oil selected from the group consisting of oils, cotton seeds, corn oil, sesame oil, soybean oil, olive oil, coconut oil, fractionated coconut oil, peanut oil, sunflower oil, safflower oil, almond oil, avocado oil, palm oil, palm kernel oil, babassu oil, butter beech nuts, oil seeds, flax, rapeseed oil and their combinations.

49. The composition according to p, where non-aqueous carrier is an oil seed cotton.

50. The composition according to p, where non-aqueous media contains dekanovu acid number of from 20 to 45% and Caprylic acid in an amount of from 45 to 80 wt.% non-aqueous media.

51. The composition according to p, where non-aqueous medium is from 0.5 to 99 wt./vol.% song.

52. The composition according to p, where non-aqueous medium is from 10 to 95 wt./vol.% song.

One on p, where non-aqueous media ranges from 40 to 90 wt./vol.% song.

54. The composition according A.25 where the specified second agent is an anesthetic agent.

55. The composition according A.25 where the specified second agent is a blocker of sodium channels.

56. Composition according to any one of p-34, which further comprises at least one excipient selected from the group consisting of antioxidants, preservatives, stabilizers, wetting agents, lubricating agents, emulsifiers, salts, influencing the osmotic pressure, dyes, alcohols and superyoshi agents.

57. Pharmaceutical composition containing a filler, which contains (a) amphiphilic oil, dispersible in water and insoluble in ethanol, (b) microcrystalline wax and (C) pharmaceutically acceptable non-aqueous carrier; the specified filler includes stably dispersed therein an antibacterial agent, an antibacterial effective amount, and a second agent containing an anti-inflammatory agent and an anesthetic in therapeutically effective amounts.

58. The composition according to 57, where the amphiphilic oil is magical 5-oleate; non-aqueous carrier is an oil-seeds, cotton, antibacterial agent includes ceftiofur or its pharmaceutically acceptable salt or form; an anti-inflammatory agent selected from groups who, consisting of deracoxib, parecoxib, celecoxib, valdecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-differenl)-3-[4-(methylsulphonyl)phenyl]-2-cyclopenten-1-it, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-differenl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulphonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-forfinal)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzosulfimide, tert-butyl 1 benzyl-4-[(4-oxopiperidin-1-yl)sulfonyl]piperidine-4-carboxylate, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzosulfimide, their salts and prodrugs; and the anesthetic is lidocaine.

59. The product containing container or a delivery vehicle having a wall permeable to oxygen, and the contained composition A.25.

60. Product by p where these walls are created from a material permeable to oxygen, including polyethylene.

61. Product by p, where the composition exhibits improved chemical and/or physical stability.



 

Same patents:

FIELD: medicine.

SUBSTANCE: can be used as method of treatment of osteomyelitis and septic arthritis, caused by bacterial agents, including with plural medicinal resistance. For this purpose mammal is introduced with pharmacologically effective amount of tigecycline separately or in combination with ryphampycine antibiotic. This agent is also offered also for manufacturing of medical products for treatment of given diseases.

EFFECT: invention provides increased efficiency of bone, marrow and joints infection treatment to preferential tigecycline distribution through bone tissue, marrow and synovial fluid.

48 cl, 5 dwg, 11 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the N" -substituted 9a-N-(N'- carbamoyl-γ-aminopropyl) and 9a-M-(M'-thiocarbamoyl-γ-aminopropyl)) derivatives of 9-desoxo-9-dihydro-9a-ase-9a-homoerythromycine A or 5-O-desosaminyl-9-desoxo-9-dihydro-9a-ase-9a-homoerythronolide A, novel semisynthetic macrolide antibiotics from the group of azalides with the common formula 1, where R means H or cladinosyl fragment, R means H, R means the isopropyl group, 1-naphtyl, 2-naphtyl, benzene, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, (3-phenylethyl, ehtoxicarbonylmethyl, 1-(1-naphtyl)ethyl, 3,4,5-trimethoxiphenyl and 2,4-dichlorphenyl, and X means O or S, or to their pharmaceutically compliant additive salts with the inorganic or organic acids and to the method of their production. The invention also relates to the pharmaceutical composition with the antibacterial activity and to the application of the compounds with the common formula 1 or their pharmaceutically compliant salts, in producing the said composition.

EFFECT: antibacterial activity.

16 cl, 26 ex, 1 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: ointment includes vegetable raw materials: sprouts and buds of poplar, aspen or willow, swallowwort (herb and blossom), common wormwood herb, yellow melilot (herb and blossom), costmary (herb and blossom), silver fir (sprouts), Siberian cedar (sprouts), pine resin and fat base, vegetable raw materials ratio is 1:10. As fat base composition contains unsalted pork fat.

EFFECT: extended range of preventive and therapeutic vegetable-based medicinal agents providing effective treatment of inflammatory diseases.

2 cl, 3 ex

FIELD: medicine; veterinary science.

SUBSTANCE: medicinal agent is spirit tincture made on basis of mixed Scotch pine buds, purple Echinacea herb and blossom clusters, horseheal rhizomes and roots, taken in proportion 2:1:1 with 70% concentrated ethyl alcohol 70% at raw and extractant ratio 1:5. Spirit tincture is exposed within 7 days in dark place at temperature 18-20°C. Calves ate treated within three courses every 48 hours with medicinal agent as 3.5-5.0% aqueous solution taken 2.0-3.0 ml/m3 during 45-60 minutes.

EFFECT: provided immunocorrection of key immunity disorders and increased natural resistivity of calves.

2 cl, 4 tbl, 6 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention is medicinal agent containing rybafutin, copolymer of lactic and glycolic acids (PLGA 50/50), D-mannitol, polysorbate 80 and dimethyl sulfoxide, as well as related method of production implying that mixed rybafutin, PLGA 50/50, D- mannitol, polysorbate 80 are heated at 50÷60°C and stirred until solid phase is completely dissolved, then cooled to room temperature, added with water at ratio 1 : 20 to 1 : 10 followed with nanoparticles˜200÷400 nm suspension produced as a result.

EFFECT: reduced toxicity of active substance accompanying maintained antimicrobic action and simplified production of end formulation.

3 cl, 4 ex, 4 tbl, 1 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: agent contains antibacterial substance of fluoroquinolones, hydrophilic base and optionally at least one adjuvant. As hydrophilic base agent contains silicone glycerohydrogel of composition Si(C3H7O3)4 · xC3H8O3 · yH2O, where 3 ≤ x ≤ 10, 20 ≤ y ≤40. As antibacterial substance of fluoroquinolones agent contains perphloxacyn, ophloxacyn, cyprophloxacyn, norphloxacyn, lomephloxacyn, moxyphloxacyn, csparphloxacyn or enoxacyn. Agent can contain as adjuvant chlorhexidine bigluconate, lydocaine hydrochloride, sea-buckthorn oil, brier oil or mixture. New agent for treatment of suppurative-inflammatory skin and soft tissues diseases including decubitus ulcers, burns, trophic ulcer, has high antibacterial effect due to wide antibacterial action (fluoroquinolones) and high transcutaneous and anti-edematous activity (silicone glycerohydrogel), and do not carry negative by-effects.

EFFECT: agent is stable, easy for keeping and well wipe-off.

6 cl, 5 dwg, 3 tbl, 6 ex

FIELD: medicine; pharmaceutics.

SUBSTANCE: pharmaceutical formulations contains as reactants 1) betamethasone dipropionate or 2) betamethasone dipropionate combined with gentamicin sulphate or 3) betamethasone dipropionate combined with gentamicin sulphate and clotrimazole. Pharmaceutical formulations contain ointment hydrophobic base containing white petrolatum and target additives - preserving agent and hydrophobic nonaqueous solvent. New pharmaceutical formulations have high antibacterial preserving action, high microbiological purity value and potentised antibacterial specific action showed by produced therapeutic effect and simultaneous prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

EFFECT: prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

18 cl, 11 tbl, 6 ex

FIELD: technological processes.

SUBSTANCE: protein variants are suggested that possess lysozyme activity. Protein-based antibacterial substance is described. DNA molecule is discovered that codes the specified protein, and also procariotic cell is discovered that contained the specified DNA molecule. Method is described to prepare protein with the help of procariotic cell.

EFFECT: simplifies preparation of antibacterial substance in commercially significant volumes.

13 cl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new derivatives of N-form hydroxylamine of the formula (I) where X means -CH2-, -CH(OH)-, -CH(OR)-,-CF2- or -CH(F) - where R meansC1-C7alkyl, R1 means phenyl, quinoline, izo quinoline, pyridyl oxypyridyl, unessentially replaced by substitutesR6, R7, R8, R9, or means a structural fragment of the formula where each of R10 and R11 independently means H, halogen; everyoneR2, R3, R4, R5 independently means H, C1-C7alkyl, n is equal to 0-2 provided that if n is equal to 0 Xmeans-CH2 everyone of R6, R7, R8, R9 H, OH independently means, halogen, C1-C7alkyl, replaced by halogen C1-C7alkyl, C1-C7alkoxy, phenyl or its pharmaceutically acceptable salt.

EFFECT: compounds display high anti-bacteria activity.

12 cl, 1 tbl, 50 ex

FIELD: medicine; chemical and pharmaceutical industry.

SUBSTANCE: gel contains, mass %: active substance - enterosgel - 10.0, preservative agent - nipagin - nipazol (3:1) - 0.2, as base: carbopol gel 0.25% or CCMA 1% or Na-CMC 4% - remaining to 100.0.

EFFECT: expressed adsorbtion properties; convenient dozing and application.

9 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention concerns method of pain relief by introduction of pharmaceutical composition containing effective amount of α-adrenergic antagonist and pharmaceutical composition, containing effective amount of the selective α-2A-antagonist.

EFFECT: method provides prolonged relief of chronic pain.

104 cl, 12 dwg, 4 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the compound with the formula (1): where R1 is C1-C12 alkyl group, which can have the substitute, or C2-C12 alkenyl group, which can have the substitute represented with the C6-C14 aryl group, which can be substituted with the halogen atoms; each of R2 and R3 represent the hydrogen atom, alkyl group, hydroxyalkyl group, dihydroxyalkyl group, or R2 and R3 form with the adjacent nitrogen atoms the 5-membered, 6-membered, or 7-membered nitrogen-containing saturated heterocyclic group, which can be substituted with the alkyl group; (the dotted line means the possible double bind), or its salt, as well as to the pharmaceutical composition containing the said compound, and to its application as a pharmaceuticals and to the treatment method.

EFFECT: invented compound demonstrates inhibiting activity against the tumor necrosis factor production (TNF-α) and improved absorbability after oral administration.

16 cl, 1 tbl, 18 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the crystal forms of methanesulfonate (A, B and C forms), methanesulfonate hydrate (F form), solvate with the acetic acid of methanesulfonate (I form), ethanesulfonate (α and β forms), hydrochloride, hydrobromide, n-toluenesulfonate or sulfate 4-(3-chlorine-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, to the methods of their production, to the pharmaceutical compositions based on them and showing the angiogenesis related activity, to the method of prevention or treatment of the disease where inhibiting angiogenesis is effective and to the application of the crystal forms in producing the pharmaceutical agent for prevention or treatment of the disease where inhibiting angiogenesis is effective.

EFFECT: producing the pharmaceutical agent for prevention or treatment of the disease where inhibiting angiogenesis is effective.

45 cl, 21 dwg, 27 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the 2-pyridone derivatives with the common formula where X, Y1, R1, Y2, G1, R5, R4, L, G2 are as specified in the invention formula. The invention also relates to the pharmaceutical agent which inhibits the human neutrophil elastase activity and which contains the compound with the formula (I), in drug manufacturing, and to the method of producing the compound with formula (I).

EFFECT: producing novel compounds which inhibit neutrophil elastase activity.

8 cl, 1 tbl, 96 ex

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical formulation for local application contain ketoprofen, solysobenzone in amount 2-4 mass.%, butylhydroxianisole in amount 0.05 to 0.2 mass.%, if required combined with pharmaceutically acceptable excipient. Composition protects ketoprofen from destruction caused by ultraviolet A, and is applied for treatment of inflammatory pathologies and musculoskeletal diseases.

EFFECT: no phototoxicity and photoallergenicity; increased permeability and rapid analgesic effect.

13 cl, 8 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention pertains to derivatives of quinoline with general formula Ia or Ib their stereoisomers and pharmaceutical salts, where X represents oxygen or sulphur, Z-CH2, Y-NO2, -C(O)OR5, -NR5SO2R5, -SO2R5 (for Ia) and -NO2 or -C(O)OR5 (for Ib). Description is also given of the method of obtaining Ia and Ib compounds, pharmaceutical compositions based on them, and their use when making medicinal preparations.

EFFECT: compounds can be used for treating lesions, related to inhibition of migration of magrophage, for example, during treatment of septic shock or arthritis.

175 cl, 16 tbl, 22 ex, 16 dwg

FIELD: chemistry.

SUBSTANCE: description is given of compounds with general formula (I)

in which R1 represents an atom of hydrogen or a C1-C4alkenyl group; R2 and R3, which can be the same or different, represent a C1-C4alkenyl group, or R2 and R3 together with a carbon atom, to which they are bonded, form a cyclic aliphatic group, containing 3-7 atoms of carbon; R4 and R5, which can be the same or different, represent a hydrogen atom or a C1-C4alkenyl group; X is chosen from a group, containing a halogen; B contains at least, one amino group with basic characteristics or a tetraalkylammonium group and can be chosen from a group, containing: NR6Y and from residue: Non-peptide compounds with formula (I) have activity of specific antagonists to B2-receptors bradykinine. Description is also given of intermediate compounds, pharmaceutical compositions.

EFFECT: possibility of using the compounds for obtaining pharmaceutical compositions for treating damages, when there is need for using a bradykinine antagonist.

11 cl, 115 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to new condensed derivatives of azolpyrimidine of formula (I), their tautomeric or stereoisomeric form and their physiologically accepted salts. Compounds of this invention have improved activity of phosphatidyl inositol-3-kinase (P13K) inhibiting, specifically of P13K-γ inhibiting, and can be applied for production of medicinal agents for prevention and treatment of P13K- and P13K-γ activity based diseases. Those diseases are inflammatory and immunoregulatory diseases such as asthma and others. In compounds of formula (I) . X means CR5R6 or NH; Y1 means CR3 or N; chemical bond between means single bond or double bond, as long as means double bond, then Y2 and Y3 mean CH, and as long as mean single bond, then Y2 and Y3 mean regardless CR3R4; Z1, Z2, Z3 and Z4 mean redardless CH , CR2 or N; R1 means phenyl, optionally containing 1 to 3 substitutes selected from group including R11, C3-8cycloalkyl, optionally containing 1 to 3 substitutes selected from group including R11, C1-6alkyl, optionally containing as substitutes one or more halogen atoms, or 3-15-component mono- or bicyclic heterocyclic ring being saturated or non-saturated, optionally containing 1 to 3 substitutes selected from group including R11, and containing 1 to 3 heteroatoms selected from group including N, O and S, where R11 means halogen, nitro-, hydroxyl-, cyano-, carboxy-, amino-, N-(C1-6alkyl)amino-, K-(hydroxyC1-6alkyl)amino-, N,N-di(C1-6alkyl)amino-, N(C1-6acyl)amino-, N-(formyl)-N-(C1-6 alkyl) amino-, N-(C1-6alkansulphonyl)amino-, N-(carboxy C1-6 alkyl)-N-(C1-6 alkyl) amino-, N-(C1-6 alkansulphonyl)amino-, N-[N,N-di(C1.6 alkyl)aminomethylene] amino-, N-[N,N-di(C1-6 alkyl)amino(C1-6 alkyl)methylene]amino-, N-[N,N-di(C1-6 alkyl)aminoC1-6alkenyl]amides, aminocarbonyl, N-(C1-6 alkyl)aminocarbonyl, N,N-di(C1-6 alkyl)aminocarbonyl, C3-8 cycloalkyl, C1-6alkylthio, C1-6 alkansulphonyl, sulphamoyl, C1-6alkoxycarbonyl, phenylC1-6alkoxycarbonyl, where specified phenylic fragment optionally contains 1 to 3 substitutes selected from group including R101, C1-6alkyl, optionally containing as substitutes 1, 2 or 3 halogen atoms, C1-6alkoxy, optionally containing as substitutes 1, 2 or 3 halogen atoms, or 5- 7-component saturated or non-saturated ring containing 1 to 3 heteroatoms selected from group containing N, and optionally containing 1 to 3 substitutes selected from group including and R101, where R101 means halogen, carboxy, amino-, N-(C1-6alkyl)amino-, N,N-di(C1-6alkyl)amino-, aminocarbonyl, N-(C1-6alkyl)aminocarbonyl, N,N-di(C1-6alkyl)aminocarbonyl, C1-6alkyl, and C1-6alkoxy; R2 mean hydroxy, halogen, nitro-, cyano-, amino-, N-(C1-6alkyl)amino-, N,N-di(C1-6alkyl)amino-, N-(hydroxyC1-6alkyl)amino-, N-(hydroxyC1-6alkyl)-N-(C1-6alkyl)amino-, C1-6 acoxy, aminoC1-6 acoxy, C2-6alkenyl, phenyl, 5-7-compound saturated or non-saturated heterocyclic ring containing 1 to 2 heteroatoms selected from group including O and N, and optionally containing as substitutes: hydrohy, d-balkyl, N-(C1-6acyl)amino-, phenyl, phenylC1-6alkyl, C1-6alkyl, optionally containing as substitutes R21, or C1-6alkoxy, optionally containing as substitutes R21, where R21 means cyano group, 1, 2 or3 halogen atoms, hydroxy, amino-, N-(C1-6alkyl)amino-, N,N-di(C1-6alkyl)amino-, C1-6alkoxy, hydroxyC1-6alkoxy, -C(O)-R201, -NHC(O)-R201, C3-8 cycloalkyl, phthalymidil, 2-oxo-1,3-oxazolidinyl, phenyl or 5- or 6-compound saturated or non-saturated heterocyclic ring containing 1 to 4 heteroatoms selected from group including O and N, and optionally containing as substitutes hydroxy, C1-6alkyl, N-(C1-6acyl)amides or benzyl, where R201 means hydroxyl, amino-, N-(C1-6alkyl)amino-, N,N-di(C1-6alkyl)amino-, N-(halogenphenylC1-6 alkyl)amides, C1-6alkyl, aminoC1-6alkyl, C1-6alkoxy, 5- or 6-compound saturated or non-saturated heterocyclic ring containing 1 to 2 heteroatoms selected from group including O and N; R3 means hydrogen, halogen, aminocarbonyl or C1-6alkyl, optionally containing as substitutes phenylC1-6alkoxy or 1, 2 or 3 halogen atoms; R4 means hydrogen or C1-6alkyl; R5 means hydrogen or C1-6alkyl; and R means halogen, hydrogen or C1-6alkyl. Invention also refers to medicinal agent, inhibition method and compound application.

EFFECT: compounds under this invention have improved activity.

16 cl, 2 tbl, 18 ex

Asaindoles // 2326880

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to pharmaceutical formulation inhibiting protein kinase, containing inhibiting selective kinase compound amount of general formula (I): , where: R means aryl or indolyl, and the latter is optionally substituted with one or more groups selected from R4, -C(=O)-R, -C(=O)-OR5, -C(=O)-NY1Y2 and -Z2R; R2 means H; R3 means H; R4 means C1-C6 alkyl, optionally substituted with one substitute -C(=O)-NY1Y2; R5 means H; R7 means C1-C6 alkyl; R means C1-C6 alkyl; X1 means C-aryl, C-heteroaryl, such as pyridile or isoxasolyl, and the latter is optionally substituted with one or two C1-C6 alkyls, C-heterocycloalkyl, such as morpholinile or peperidynil, C-halogen, C-CN, C-OH, C-Z2R, C-C(=O)-OR5, C-NYlY2, C-C(=O)-NY1Y2; Y1 and Y2 means redardless H, aryl, C3-C6 cycloaryl, C1-C6 alkyl, optionally substituted with one group selected from phenyl, halogen, heterocyclil, such as morpholinile, phurile, hydroxyl, -C(=O)-OR5, OR7; or group-NY1Y2 can form morpholinile, peperidynil, optionally substituted with one or two substitutes selected from OH, C1-C6 alkyl; Z means O; where aryl as group or part of group means optionally substituted with one or two substitutes monocyclic aromatic C6carbocyclic fragment, where substitute is selected from halogen or C1-C6 alkoxy, C(=O)-OR5; except compounds: 4-chlorine-2-(4-tert-butylphenyl)-1H-pyrrole[2,3-b]pyridine, 2-(5-methoxy-1 -methyl-1 H-indole-3-il)-4-phenyl-1H- pyrrole[2,3-b]pyridine, 2-(5- methoxy-1 -methyl-1 H-indole-3-il)-1H- pyrrole[2,3-b] pyridine-4-carbonitrile, 4-chlorine-2-(5- methoxy-1 -methyl-1H-indole-3-il)-1H- pyrrole[2,3-b]pyridine, or 2-(5- methoxy-1H-indole-3-il)-1H- pyrrole[2,3-b]pyridine -4- carbonitrile.

EFFECT: application of compound for production of medicinal agent for inflammatory disease.

51 cl, 9 tbl, 148 ex

FIELD: chemistry.

SUBSTANCE: invention refers to cyanoguanidine derivatives of the general formula I in which A, A, X1, X2, X3, Y1, Y2, Y3, R1, R2, R5, R6 and n have the values indicated in the formula of the invention. The invention also refers to the pharmaceutical composition which has antiproliferative activity on the basis of the compound of the formula I, and application of these compounds for medicinal preparation aimed at treatment and alleviation of proliferative disease and conditions.

EFFECT: new compounds can be useful at proliferative disease treatment.

25 cl, 5 ex

FIELD: medicine; pharmacology.

SUBSTANCE: proposed suppository along with consistent base (lipophilic, hydrophilic or diphilic) and stabiliser selected from chlorhexidine bigluconate, nypagine and sodium carboxymethyl cellulose as natural endogenous interferon inductor, is supplied with sodium salt complex of alpha-helical and double-helical RNA from killer yeast Saccharomyces cerevisiae. Quantitative amount of specified ingredients per suppository of mass 1.0 g is: sodium salt complex of alpha-helical and double-helical RNA from killer yeast Saccharomyces cerevisiae - 50-150 mcg; stabiliser - 10-30 mcg; additives - others.

EFFECT: extended range of therapeutic antiviral agents and reduced toxicity with maintained efficiency.

6 cl, 4 ex, 3 tbl

Up!